{"id":"sr-a-epratuzumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL2108404","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"SR-A is a selective Bruton's tyrosine kinase (BTK) inhibitor that suppresses B cell activation and survival, while epratuzumab is a monoclonal antibody targeting CD19 on B cell surfaces. Together, they work synergistically to reduce pathogenic B cell populations and autoimmune responses in lupus patients.","oneSentence":"SR-A combined with epratuzumab targets CD19-positive B cells to deplete autoreactive B cells in systemic lupus erythematosus.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:36:03.101Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE)"}]},"trialDetails":[{"nctId":"NCT07476729","phase":"PHASE3","title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-04-01","conditions":"B-Cell Acute Lymphoblastic Leukaemia","enrollment":750},{"nctId":"NCT01802814","phase":"PHASE3","title":"International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2014-05","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":700}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Epratuzumab"],"phase":"phase_3","status":"active","brandName":"SR-A + Epratuzumab","genericName":"SR-A + Epratuzumab","companyName":"Charite University, Berlin, Germany","companyId":"charite-university-berlin-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SR-A combined with epratuzumab targets CD19-positive B cells to deplete autoreactive B cells in systemic lupus erythematosus. Used for Systemic lupus erythematosus (SLE).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}